18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma
Trial ID or NCT#
NCT04365660
Status
NOT RECRUITING
Purpose
The purpose of this ÌÇÐÄ´«Ã½ is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").
Official Title
A Phase 2 Study of 18F FTC 146 PET/CT in Patients With Newly Diagnosed Osteosarcoma
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
- * Patients with biopsy proven osteosarcoma requiring local surgical intervention.* ECOG ≤ 2* Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- * Chemotherapy in the past 2 months.* Prior history of allergic reaction to 18F FTC 146.* Pregnant or nursing
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Denise Montes
650-725-4185
View on